ImmuPharma plc (LON:IMM – Get Free Report) fell 15.1% during mid-day trading on Friday . The stock traded as low as GBX 3.28 and last traded at GBX 3.38. 2,337,142 shares changed hands during trading, a decline of 5% from the average session volume of 2,465,374 shares. The stock had previously closed at GBX 3.98.
ImmuPharma Price Performance
The firm’s fifty day simple moving average is GBX 3.87 and its 200 day simple moving average is GBX 4.44. The company has a market capitalization of £21.09 million, a price-to-earnings ratio of -9.14 and a beta of 3.01.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 633.14%. Equities research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
